European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease ...

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

The company said benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain ...

Pfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an ...

Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...

Pfizer Inc. (NYSE:PFE) said the company is voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of ...

The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and ...

It's a blow to the SCD community, as Oxbryta (voxelotor) was the first drug to reach the market that prevented sickle ...

Pfizer has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) approved for treating sickle cell disease ...

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

The introduction of an FDA-approved drug didn't turn out the way buyer or seller hoped. Pfizer Inc. is pulling the sickle ...